Methods and Devices For Treating Intervertebral Disc Disease
Provided are methods for treating intervertebral disc degeneration, promoting tissue regeneration in the intervertebral disc, promoting homeostasis of the intervertebral disc, preventing intervertebral disc degeneration, and reducing inflammation of the intervertebral disc in a subject in need thereof comprising administering a myeloid differentiation primary response (88) (MyD88) antagonist to the subject. Also provided is a device, biomaterial or putty for implantation in or near the spine, wherein the device, biomaterial or putty is coated or infused with a myeloid differentiation primary response gene (88) (MyD88) antagonist.
1 . A method for treating or preventing intervertebral disc degeneration in a subject in need thereof comprising administering a myeloid differentiation primary response (88) (MyD88) antagonist to the subject.
2 . The method of claim 1 wherein said myeloid differentiation primary response (88) (MyD88) antagonist is delivered locally in the vicinity of the intervertebral disc.
3 . The method of claim 2 wherein said administering comprises implanting an intervertebral device, biomaterial, or putty.
4 . The method of claim 3 wherein the myeloid differentiation primary response (88) (MyD88) antagonist is delivered from an implantable device coated with a myeloid differentiation primary response (88) (MyD88) antagonist.
5 . The method of claim 4 wherein said myeloid differentiation primary response (88) (MyD88) antagonist is a nucleic acid, peptide, protein, antibody or antigen-binding fragment thereof.
6 . The method of claim 5 wherein the myeloid differentiation primary response (88) (MyD88) antagonist is a peptide.
7 . The method of claim 6 wherein the peptide comprises the amino acid sequence of SEQ ID NO: 22.
8 . The method of claim 7 wherein said myeloid differentiation primary response (88) (MyD88) antagonist prevents homodimerization of MyD88.
9 . The method of claim 5 wherein the nucleic acid is an RNAi agent.
10 . The method of claim 9 wherein the RNAi agent is siRNA, shRNA, miRNA, dsRNA or ribozyme or variants thereof
11 . The method of claim 8 wherein the subject is a mammal
12 . The method of claim 11 wherein the mammal is a human.
13 . A device for implantation in or near the spine, wherein said device is coated or infused with a myeloid differentiation primary response gene (88) (MyD88) antagonist.
14 . The device of claim 13 wherein said device is for implantation in an intervertebral space.
15 . The device of claim 14 wherein said myeloid differentiation primary response (88) (MyD88) antagonist is a nucleic acid, peptide, protein, antibody or antigen-binding fragment thereof.
16 . The device of claim 15 wherein the myeloid differentiation primary response (88) (MyD88) antagonist is a peptide.
17 . The device of claim 16 wherein the peptide comprises the amino acid sequence of SEQ ID NO: 22.
18 . The device of claim 17 wherein said myeloid differentiation primary response gene (88) (MyD88) antagonist prevents homodimerization of myeloid differentiation primary response (88) (MyD88).
19 . The device of claim 15 wherein the nucleic acid is an RNAi agent.
20 . The device of claim 19 wherein the RNAi agent is siRNA, shRNA, miRNA, dsRNA or ribozyme or variants thereof.
21 . A biomaterial for implantation in or near the spine, wherein said biomaterial is coated or infused with a myeloid differentiation primary response gene (88) (MyD88) antagonist.
22 . The biomaterial of claim 21 wherein said biomaterial is for implantation in an intervertebral space.
23 . The biomaterial of claim 22 wherein said myeloid differentiation primary response (88) (MyD88) antagonist is a nucleic acid, peptide, protein, antibody or antigen-binding fragment thereof.
24 . The biomaterial of claim 23 wherein the myeloid differentiation primary response (88) (MyD88) antagonist is a peptide.
25 . The biomaterial of claim 24 wherein the peptide comprises the amino acid sequence of SEQ ID NO: 22.
26 . The biomaterial of claim 25 wherein said myeloid differentiation primary response gene (88) (MyD88) antagonist prevents homodimerization of myeloid differentiation primary response (88) (MyD88).
27 . The biomaterial of claim 23 wherein the nucleic acid is an RNAi agent.
28 . The biomaterial of claim 27 wherein the RNAi agent is siRNA, shRNA, miRNA, dsRNA or ribozyme or variants thereof.
29 . A putty for implantation in or near the spine, wherein said putty is coated or infused with a myeloid differentiation primary response gene (88) (MyD88) antagonist.
30 . The putty of claim 29 wherein said putty is for implantation in an intervertebral space.
31 . The putty of claim 30 wherein said myeloid differentiation primary response (88) (MyD88) antagonist is a nucleic acid, peptide, protein, antibody or antigen-binding fragment thereof.
32 . The putty of claim 31 wherein the myeloid differentiation primary response (88) (MyD88) antagonist is a peptide.
33 . The putty of claim 32 wherein the peptide comprises the amino acid sequence of SEQ ID NO:22.
34 . The putty of claim 33 wherein said myeloid differentiation primary response gene (88) (MyD88) antagonist prevents homodimerization of myeloid differentiation primary response (88) (MyD88).
35 . The putty of claim 31 wherein the nucleic acid is an RNAi agent.
36 . The putty of claim 35 wherein the RNAi agent is siRNA, shRNA, miRNA, dsRNA or ribozyme or variants thereof.